Vaxcyte, Inc.
PCVX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PCVX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCVX
Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial diseases, with a focus on pneumococcal conjugate vaccines for adults and pediatric populations.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$8.90B
Cash Runway
18.6 moLead Asset
vax-24 (Phase 2)
Next Catalyst
Phase3_Topline · Jan 1, 2027Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 7 clinical trials · 3 catalysts for Vaxcyte, Inc..
Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial diseases, with a focus on pneumococcal conjugate vaccines for adults and pediatric populations.
- Vaxcyte has incurred net losses each year since inception and expects to continue incurring net losses in the foreseeable future [sec_mda · as of 2025-05-07].
- As of June 30, 2026, the company reported cash and equivalents of $184.7 million and shareholders' equity of $3,071.3 million [sec].
- The company is advancing vaccine candidates VAX-31 and VAX-24 through clinical trials, with Phase 3 topline data expected in early 2027 [catalyst].
- Vaxcyte does not expect to generate revenue from product sales until it obtains regulatory approval for one or more candidates, which is expected to take several years [sec_mda · as of 2026-05-06].
- The company has raised substantial capital but will need additional funding to complete development, manufacturing, and commercialization of its candidates [sec_mda · as of 2026-02-24].
What works
- Vaxcyte has a strong cash position with $3.1 billion in shareholders' equity as of June 30, 2026, providing a substantial runway for ongoing operations [sec].
- The company's lead vaccine candidates, VAX-31 and VAX-24, target large markets in adult and pediatric pneumococcal vaccination, with Phase 3 trials underway [catalyst].
- Management includes experienced leadership from the pharmaceutical industry, including a former President of Merck Global Vaccines [sec_mda · as of 2026-08-05].
What to weigh
- Vaxcyte has no approved products or revenue from commercial sales, and it expects to remain pre-revenue for several years [sec_mda · as of 2026-05-06].
- The company has a history of net losses, with a net loss of $284.3 million for the six months ended June 30, 2026 [sec].
- Vaxcyte will need to raise substantial additional capital to complete development and commercialization, which may dilute existing shareholders [sec_mda · as of 2026-02-24].
- The company has discontinued development of certain candidates (VAX-A1, VAX-GI, VAX-PG) due to insufficient efficacy signals, highlighting pipeline risk [sec_mda · as of 2025-08-06].
From the filings
Quoted directly from source documents.
Vaxcyte has incurred net losses each year since inception and expects to continue incurring net losses.
“We have incurred net losses in each year since inception and expect to continue to incur net losses in the foreseeable future.”
SEC MD&A · May 7, 2025
The company does not expect to generate revenue from product sales until regulatory approval is obtained.
“We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our vaccine candidates, which we expect will take a number of years.”
SEC MD&A · May 6, 2026
Vaxcyte will need to raise substantial additional capital to complete development and commercialization.
“We have raised substantial capital; however, we will need to raise substantial additional capital to complete development, manufacturing and commercialization of our drug candidates.”
SEC MD&A · February 24, 2026
The company discontinued development of VAX-PG due to insufficient efficacy signals.
“Additionally, we discontinued further development of VAX-PG. VAX-PG preclinical data demonstrated an acceptable safety profile but not sufficient efficacy signals to warrant further investment.”
SEC MD&A · August 6, 2025
Catalyst timeline
- 2027-01-01 · Phase 3 Topline for VAX-31/VAX-24 (adult/pediatric) — Topline data from a Phase 3 randomized, double-blind, active-controlled study evaluating safety and tolerability of a vaccine candidate.
- 2027-03-01 · Phase 3 Topline for VAX-31/VAX-24 (pediatric) — Topline data from a Phase 3 randomized, double-blind, placebo-controlled study evaluating safety and tolerability of a vaccine candidate.
- 2027-03-01 · Phase 3 Topline for VAX-31/VAX-24 (adult) — Topline data from a Phase 3 randomized, double-blind, active-controlled study evaluating safety and tolerability of a vaccine candidate.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Vaxcyte has no commercial products and expects no revenue for several years, relying entirely on funding [sec_mda · as of 2026-05-06].
- Need for additional capital — The company will require substantial additional funding to complete development and commercialization, with potential dilution [sec_mda · as of 2026-02-24].
- Clinical and regulatory uncertainty — Phase 3 trials for VAX-31 and VAX-24 may fail to meet endpoints, delaying or preventing approval [catalyst].
- Pipeline attrition — Discontinued programs (VAX-A1, VAX-GI, VAX-PG) show risk of candidate failure [sec_mda · as of 2025-08-06].
What to watch
- Phase 3 topline data for VAX-31 and VAX-24 expected in early 2027 [catalyst].
- Any updates on regulatory interactions or potential approval timelines for lead candidates [sec_mda · as of 2026-05-06].
- Future financing events, as the company will need additional capital to fund operations beyond its current cash runway [sec_mda · as of 2026-02-24].
- Progress in manufacturing scale-up for potential commercial launches [sec_mda · as of 2026-05-06].
Sources: Catalysts · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Vaxcyte, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vaxcyte, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
18.6 months
D/E 0.14 · 0% dilution
Lead: Phase 3
5 candidates
3 upcoming, next in ~124d
0 buys · 41 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
335
Total value held
$9.82B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 33,151,750 | $1.92B |
| fmr llc | 16,492,861 | $958.4M |
| vanguard capital management llc | 12,533,402 | $728.3M |
| ra capital management, l.p. | 11,474,599 | $666.8M |
| blackrock, inc. | 10,971,816 | $637.6M |
| vanguard portfolio management llc | 6,279,545 | $364.9M |
| wellington management group llp | 5,614,597 | $326.3M |
| state street corp | 4,440,519 | $258.0M |
| deep track capital, lp | 4,300,000 | $249.9M |
| westfield capital management co lp | 3,646,138 | $211.9M |
Showing top 10 of 335 institutional holders of Vaxcyte, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.0%
- Days to cover
- 10.7
- Shares short
- 14,356,548
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PCVX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vaxcyte, Inc.?
Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial diseases, with a focus on pneumococcal conjugate vaccines for adults and pediatric populations.
What is Vaxcyte, Inc.'s lead drug candidate?
Vaxcyte, Inc.'s most advanced tracked candidate is vax-24 (Phase 2) for Pneumococcal Vaccines.
What is Vaxcyte, Inc.'s next catalyst?
Vaxcyte, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolera" — expected January 1, 2027.
Who is the CEO of Vaxcyte, Inc.?
Mr. Grant E. Pickering M.B.A. is the chief executive officer of Vaxcyte, Inc. (PCVX).
Where is Vaxcyte, Inc. headquartered?
Vaxcyte, Inc. (PCVX) is headquartered in San Carlos, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.